Lenvatinib has proved to be an effective but quite toxic therapeutic tool for differentiated thyroid carcinomas (DTCs), with two third of pts needing dose reduction and 14.2% discontinuing treatment in the SELECT trial [1]. Severe bleeding has been reported as one of the main cause of death in DTC pts treated with multi-target TKI [2].
http://ift.tt/2wcKXr2
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου